4
Sponsors
Galecto Biotech AB, Seoul National University Hospital
Conditions
Advanced liver Fibrosis and CirrhosisNon-small Cell Lung CancerStudy to investigate the safety and efficacy of GB1211 (a galectin-3 inhibitor) in combination with atezolizumab in patients with Non-Small Cell Lung Cancer (NSCLC).Tinnitus
Phase 1
An Open-label, Randomized, Three-period, Crossover Study to compare the Pharmacokinetics of GB1211 upon dosing a capsule under fasting condition and a tablet under fasting and fed conditions in healthy volunteers.
CompletedCTIS2022-502200-67-00
Start: 2022-12-27End: 2023-04-10Target: 12Updated: 2023-04-04
An open label study followed by a randomised, double-blind, placebo-controlled, parallel group and an extension study to investigate the safety and efficacy of GB1211 (a galectin-3 inhibitor) in combination with atezolizumab in patients with Non-Small Cell Lung Cancer (NSCLC).
CompletedCTIS2024-514419-93-00
Start: 2022-05-19End: 2025-11-20Target: 49Updated: 2025-03-05